- Home
- CUE vs MCHX Comparison
CUE vs MCHX Comparison
Compare CUE & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | MCHX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 71.6M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CUE | MCHX |
|---|---|---|
| Price | $0.30 | $1.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 17.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,100,000.00 | ★ $46,494,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $6.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $1.26 |
| 52 Week High | $1.75 | $2.31 |
Technical Indicators
Market Signals| Indicator | CUE | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 49.67 |
| Support Level | $0.23 | $1.60 |
| Resistance Level | $0.51 | $1.73 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.36 | 37.36 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About MCHX Marchex Inc. Class B
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.